Merestinib is primarily used in the field of oncology as an investigational drug targeting various cancers. It functions as a multi-kinase inhibitor, meaning it blocks several enzymes involved in cancer cell growth and survival. This makes it particularly effective in treating cancers with specific genetic mutations or overactive kinase pathways. It has shown promise in clinical trials for conditions such as non-small cell lung cancer, cholangiocarcinoma, and other solid tumors. By inhibiting key kinases like MET, ROS1, and MKNK1, Merestinib disrupts signaling pathways that promote tumor progression, potentially slowing or stopping cancer growth. Its application is often explored in combination with other therapies to enhance treatment efficacy.